Skip to main content
CPHI logo

China Pharma Holdings, Inc. (CPHI) Stock Price & Analysis

China Pharma Holdings, Inc. (CPHI) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $0.4384 (-13.00%), as of the Nov 20, 2026 trading session; market cap $18.9M.

Educational signal · not a buy or sell recommendation · How to read this

$0.4384 −$0.0655 (-13.00%) Market Cap $18.9M

China Pharma Holdings, Inc. · CPHI · AMEX

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical and biochemical products in China. The company offers a range of generic and branded products, including injectables, tablets, and capsules, targeting hospitals and private retailers.

Price as of Nov 20, 2026

Key Statistics

23 of 100

MoonshotScore v2 · China Pharma Holdings (CPHI)

Weak
Business Quality Thin (23)
Financial Safety Strained (27)
Valuation Full (52)
Growth Durability Shrinking (10)
Momentum Slipping (24)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.

  • Altman Z -0.48 · Piotroski F 3
  • ROE -21.0% · ROA -9.4% · current ratio 0.26

Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CPHI (53 recorded, newest six shown)
RecordedScoreBand
24Weak
23Weak
23Weak
23Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.4384
Change on the day-13.00%
Market capitalisation$18.9M—
Shares traded on the day32.8K

Price & events

Other perspectives

Council score for China Pharma Holdings (CPHI): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Neutral
Growth Durability Negative
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Moderate
ROE Negative
Gross Margin Weak

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is China Pharma Holdings (CPHI), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. China Pharma Holdings, Inc. (CPHI) is listed on AMEX. It employs 215 people. The market values it at $18.9M.

3 · Financial strengths and risks

What are the financial strengths and risks for China Pharma Holdings (CPHI)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -0.48 · Piotroski F 3. Trailing ratios: ROE -21.0% · ROA -9.4% · current ratio 0.26.

Data-derived red flags

  • Listing risk — at $0.4384 the shares sit below the $1.00 minimum bid AMEX requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -0.48 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-21.0%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does China Pharma Holdings compare with its peers?

Short answer

China Pharma Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Incannex Healthcare Limited (IXHL) Same industry, near in market value$1.86 Nov 20, 2026$23.3M48 5-pillar Nov 18, 2026
Organigram Global Inc. (OGI) Same industry, near in market value$0.58 Nov 20, 2026$82.3M35 5-pillar Nov 18, 2026
TherapeuticsMD, Inc. (TXMD) Same industry, near in market value$1.71 Nov 20, 2026$19.8M34 5-pillar Nov 18, 2026
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Same industry, near in market value$3.49 Nov 20, 2026$16.6M32 5-pillar Nov 18, 2026
Universe Pharmaceuticals Inc. (UPC) Same industry, near in market value$1.36 Nov 19, 2026$6.83M32 5-pillar Nov 18, 2026
Zhengye Biotechnology Holding Limited (ZYBT) Same industry, near in market value$1.52 Nov 19, 2026$72.0M32 5-pillar Nov 18, 2026
Talphera, Inc. (TLPH) Same industry, near in market value$0.79 Nov 20, 2026$40.8M31 5-pillar Nov 18, 2026
InterCure Ltd. (INCR) Same industry, near in market value$3.24 Nov 20, 2026$42.0M30 5-pillar Nov 18, 2026
Quantum BioPharma Ltd. (QNTM) Same industry, near in market value$1.29 Nov 20, 2026$8.29M30 5-pillar Nov 18, 2026
Rockwell Medical, Inc. (RMTI) Same industry, near in market value$5.82 Nov 20, 2026$23.1M25 5-pillar Nov 18, 2026
Aytu BioPharma, Inc. (AYTU) Same industry, near in market value$2.66 Nov 20, 2026$28.9M25 5-pillar Nov 18, 2026
Biofrontera Inc. (BFRI) Same industry, near in market value$0.57 Nov 19, 2026$10.2M25 5-pillar Nov 18, 2026
China Pharma Holdings (CPHI) — this page$0.4384$18.9M23

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
2
Purchases
0
Sales
0
Other transactions
12

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CPHI in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CPHI in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about China Pharma Holdings (CPHI)?

Read these with our analysis →

Common Questions About CPHI

These answers are editorial: 1 of these 9 answers is drawn from the CPHI research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CPHI?

CPHI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical and biochemical products in China.

Is CPHI a good stock to buy?

Stock Expert AI does not rate CPHI buy, sell or hold. China Pharma Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CPHI stock price today?

The last price recorded for China Pharma Holdings, Inc. (CPHI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about CPHI stock?

Analyst coverage of China Pharma Holdings, Inc. is limited due to its small market capitalization and financial challenges. Key valuation metrics reflect the company's current struggles, including negative profit and gross margins.

What are the key factors to evaluate for CPHI?

China Pharma Holdings, Inc. (CPHI) holds a MoonshotScore in the low range. By investing in research and development and strategic partnerships, CPHI can introduce new products and increase its market share. Not financial advice.

How frequently does CPHI data refresh on this page?

CPHI's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CPHI's recent stock price performance?

China Pharma Holdings, Inc. (CPHI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese pharmaceutical market. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CPHI overvalued or undervalued right now?

China Pharma Holdings, Inc. (CPHI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CPHI before investing?

Before investing in China Pharma Holdings, Inc. (CPHI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 10 figures on this page — 6 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.